BDB-001 is under clinical development by Eikon Therapeutics and currently in Phase I for Squamous Non-Small Cell Lung Cancer. According to GlobalData, Phase I drugs for Squamous Non-Small Cell Lung Cancer have an 89% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how BDB-001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BDB-001 overview
BDB-001 is under development for the treatment of solid tumors including bladder cancer, ER+ breast cancer, HER2+ cancer, triple negative breast cancer, colorectal cancer, esophogeal cancer, gastric cancer, non-squamous non-small cell lung cancer, squamous non-small cell lung cancer, melanoma, prostate cancer, renal cell cancer, merkel cell carcinoma (MCC), cutaneous squamous cell carcinoma (cSCC), urothelial carcinoma, head and neck cancer, pancreatic cancer, cervical cancer, nasopharyngeal cancer, kaposi sarcoma and soft tissue sarcoma. The drug candidate acts by targeting toll-like receptor 7/8 (TLR 7/8). It is adminsitered through intravenous route.
Eikon Therapeutics overview
Eikon Therapeutics is a clinical-stage biotechnology company that carries out drug discovery and development. The company provides preclinical programs in the fields of oncology, neuroscience and immunology as well as clinic programs designed to improve cancer treatment. Its oncological pipeline products include TLR7/8 – BDB001 and PARP1 selective inhibitors – IMP1734 and IMP17307. The company utilizes technology such as single molecule tracking and super-resolution fluorescence microscopy the interface of biology, engineering and chemistry to discover novel treatments for life-threatening diseases. Eikon Therapeutics is headquartered in Hayward, California, the US.
For a complete picture of BDB-001’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
